Literature DB >> 30420

Protection of rats from compound 48/80-induced lethality. A simple test for inhibitors of mast cell-mediated shock.

C J Niemegeers, F Awouters, S de Nollin, P A Janssen.   

Abstract

The dose of 0.5 mg/kg i.v. of compound 48/80 was lethal in 97.2% of the injected rats. Observations before death and at autopsy were in accordance with the basic effect of compound 48/80 in rats i.e. the sustained release of mast cell mediators, whose action on the cardiovascular system leads to circulatory collapse. The administration of drugs with various pharmacological effects before the intravenous challenge with compound 48/80 allowed us to conclude that the following effects are not sufficient to prevent the lethal shock: inhibition of prostaglandin biosynthesis; H2-histamine antagonism; cholinergic, alpha- or beta-adrenergic blockade; beta-adrenergic stimulation; CNS-effects of antidepressants, hypnotics, sedatives, neuroleptics or narcotic analgesics; ganglion blockade; glucocorticoid or cromoglycate-like activity. Dose-dependent protection from the lethal reaction was obtained with compounds known to exert a single or several actions of the following types: oxatomide-like inhibition of mast cell mediator release; h1-histamine antagonism; serotonin antagonism. Quantitatively, however, when measured in in vitro systems these effects are poorly related to the protection from lethal compound 48/80 challenge. The new test offers the advantage of a simple, comprehensive measure of the potency of a compound to prevent mast cell-mediated shock.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 30420

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  7 in total

1.  Prediction of the Bobon clinical profile of neuroleptics from animal pharmacological data.

Authors:  J Kelder
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

2.  The pharmacological profile of a specific, safe, effective and non-sedative anti-allergic, astemizole.

Authors:  C J Niemegeers; F Awouters; P A Janssen
Journal:  Agents Actions       Date:  1986-04

3.  Antihistaminic/antiallergic activity of 2-dialkylaminoalkylthio(oxy)-1-substituted benzimidazoles: evaluation "in vitro" and "in vivo".

Authors:  S Dini; G F Caselli; C Basilico; A Lavezzo; R Giani
Journal:  Agents Actions       Date:  1990-04

4.  Bromperidol, a new butyrophenone neuroleptic: a review.

Authors:  B Dubinsky; J L McGuire; C J Niemegeers; P A Janssen; H S Weintraub; B E McKenzie
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

5.  Levocabastine: pharmacological profile of a highly effective inhibitor of allergic reactions.

Authors:  F Awouters; C J Niemegeers; T Jansen; A A Megens; P A Janssen
Journal:  Agents Actions       Date:  1992-01

6.  Effects of potential blood substitutes (perfluorochemicals) on rat liver and spleen.

Authors:  J Lutz; P Metzenauer
Journal:  Pflugers Arch       Date:  1980-09       Impact factor: 3.657

7.  Antiemetic specificity of dopamine antagonists.

Authors:  C J Niemegeers
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.